-transparent.png){kind=logo}
Thirty-seven patients with disseminated breast cancer refractory to previous therapy were treated with a combination of mitomycin, doxorubicin, and vinblastine (MAV). One complete and eight partial responses were achieved, with an overall response rate of 24.3%. The median duration of response was 5+ months. The MAV regimen had generally moderate but acceptable toxicity. This study indicates that the MAV combination is no better than doxorubicin given as a single agent.
Related Publications
R Borovik, and
R Epelbaum, and
Y Cohen, and
E Robinson
January 1986,
Cancer chemotherapy and pharmacology,
R Borovik, and
R Epelbaum, and
Y Cohen, and
E Robinson
September 1981,
Cancer,
R Borovik, and
R Epelbaum, and
Y Cohen, and
E Robinson
January 1993,
Breast cancer research and treatment,
R Borovik, and
R Epelbaum, and
Y Cohen, and
E Robinson
September 1998,
Bulletin du cancer,
R Borovik, and
R Epelbaum, and
Y Cohen, and
E Robinson
July 1984,
European journal of cancer & clinical oncology,
R Borovik, and
R Epelbaum, and
Y Cohen, and
E Robinson
January 1992,
Breast cancer research and treatment,
R Borovik, and
R Epelbaum, and
Y Cohen, and
E Robinson
February 1992,
Annals of oncology : official journal of the European Society for Medical Oncology,
R Borovik, and
R Epelbaum, and
Y Cohen, and
E Robinson
January 1989,
Oncology,
R Borovik, and
R Epelbaum, and
Y Cohen, and
E Robinson
October 1984,
Cancer,
R Borovik, and
R Epelbaum, and
Y Cohen, and
E Robinson
January 1988,
Acta oncologica (Stockholm, Sweden),
